Clinical Trials: More than safety and efficacy
January 27, 2015 /3BL Media/ – Clinical trials are a crucial part of the development process for human medicines. Without clinical trials pharmaceutical companies would be unable to document the efficacy, safety and optimal use of new medicines, limiting access to improved treatments.
Developing innovative products that address unmet needs in the treatment of diabetes can only take place through collaborations. Novo Nordisk’s latest Blueprint for Change report, Assessing the value of diabetes clinical research, shows how clinical research is not only helping to improve treatment but also benefiting stakeholders involved, including patients, healthcare professionals and local communities.
Peter Kristensen, senior vice president of Global Development at Novo Nordisk explains: “We spend considerable time and resources on conducting clinical research in Novo Nordisk. For a long time, there has been a consensus that value is created for stakeholders in the process; however, no studies have profoundly investigated how this value is created, who receives it and how much is generated. This study helps answering some of these questions and will be important for the future dialogue and collaboration with these and other stakeholders.”
The new Blueprint for Change report documents how clinical research also enhances hospital/clinical capabilities, drives scientific progress and has a positive impact on the surrounding economy. The analysis shows how value is added by increasing patients’ understanding of their disease, improving diagnosis and treatment procedures in clinics and creating jobs in the local community. Key findings from the report include 80% of patients surveyed said that their involvement in a clinical trial improved their HbA1c levels, 74% of healthcare professionals have diagnosed one or more diabetes complications during trials and 71% of patients improved their eating habits as a result of a clinical trial.
“Our hope is that the study will be a catalyst for discussions on what clinical research is and how we further improve our collaboration to create even more value for all stakeholders involved and society at large,” says Peter Kristensen.
About Assessing the value of diabetes clinical research
Assessing the value of diabetes clinical research is the latest case study from Novo Nordisk’s Blueprint for Change Programme. The programme aspires to set a standard for measuring and optimising the impact of Novo Nordisk’s activities by enhancing understanding of how Novo Nordisk creates value through its Triple Bottom Line business principle.
Through a series of case studies, Novo Nordisk provides insight into current and emerging sustainable business approaches, as well as best practices for creating shared value. The intent of the Blueprint for Change programme is not to present final answers, but rather a work in progress that invites stakeholders to share their own views and together co-innovate sustainable solutions to complex societal issues.
Read more about Novo Nordisk’s Blueprint for Change Programme